ACT Brief: Portfolio-Level Recruitment Strategy, Structural Change Through Systems Thinking, and Kidney Function Preservation in IgAN

This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.

• In a new FAQ, we addressed how the FDA's shift to single pivotal trials raises recruitment stakes for sponsors, requiring movement from study-by-study outreach to programmatic, relationship-based approaches. Success requires portfolio-level funding, cross-study governance, and integration of behavioral readiness screeners with clinical eligibility, treating patient engagement as long-term strategic capability rather than per-study operational task.
• In a new contributed article, Kelsey Jakee, senior director of portfolio strategy and innovation at TransCelerate BioPharma, examined why clinical R&D modernization stalls through incremental optimization of individual workflows. Meaningful systemic change requires leaders to visualize structural relationships, understand hidden incentives, and identify leverage points that benefit the whole system, moving beyond siloed solutions toward interoperable models that prioritize long-term efficiency over short-term convenience.
• FDA converted Fabhalta's accelerated approval to traditional approval based on Applause-IgAN Phase III data showing benefit in kidney function decline versus placebo over two years. The conversion from proteinuria reduction to kidney function preservation as the approval anchor strengthens the linkage to clinically meaningful outcomes such as dialysis and transplantation risk reduction.

That's all for today's ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.